Viyash Scientific Acquires Italy's BioForLife to Boost European Companion Animal Health Presence

Viyash Scientific Acquires Italy's BioForLife to Boost European Companion Animal Health Presence​

Viyash Scientific Limited, through its subsidiary Alivira Animal Health Limited, has agreed to acquire 100% of the stake in BioForLife Italia S.r.l., a leading pet care company based in Milan, Italy. The acquisition is structured as a cash consideration deal valued at approximately ₹ 188 crore and is expected to be finalized during Q2 FY27.

The transaction marks a significant strategic move for Viyash Scientific, aiming to capitalize on the rapidly growing Companion Animal Health Generics market. This move specifically expands Alivira's global presence in companion animal health and strengthens its standing within Europe's pet care sector.

Italy is recognized as one of the five largest animal health markets in Europe, with companion animal care emerging as its fastest-growing segment. The growth is attributed to increasing pet humanization trends, rising rates of pet ownership, and heightened spending on specialized and preventive veterinary care.

BioForLife specializes in the development, commercialization, and distribution of various pet care products. BFL possesses a robust product portfolio and pipeline across nutritional complements, pharmaceuticals, and rapid diagnostic tests. Furthermore, the company is expanding its business presence into high-growth segments such as dermatology and ophthalmology.

A key operational asset of BioForLife is its well-established sales team, which reaches over 80% of all veterinary clinics in Italy, providing strong customer relationships to support future growth initiatives. The acquisition provides a platform for Alivira to launch new products from its pipeline in Italy. It also offers opportunities to expand the BFL range into other markets managed by the Alivira group across Europe, the Middle East, Asia, and Latin America.

Commenting on the strategic importance of the deal, Dr. Haribabu Bodeputi, Managing Director and Group CEO of Viyash Scientific Limited, stated that the acquisition is a crucial step in building a leading global Companion Animal Health business. He noted that BioForLife offers an established platform in Italy, one of Europe’s most attractive pet care markets, which strengthens the company's regional presence.

Dr. Bodeputi added that the combination of BioForLife's commercial reach and Alivira's product development capabilities presents a compelling opportunity to accelerate growth. This synergy is aimed at delivering greater value to veterinarians, pet owners, and partners across various markets. The investment also signifies a commitment to sustainable growth and long-term value creation by introducing innovative products into India and other geographies using the company’s global network.

The transaction will see BFL executives integrated into the Alivira team to continue managing business operations and drive new growth initiatives. This acquisition builds upon Alivira's track record of international acquisitions in animal health, having successfully integrated companies across Europe, Asia, and Latin America over the past decade.

VIYASH Stock Price Movement​

As of 12:56 PM, shares of Viyash Scientific Limited are slipping slightly in live trading, currently standing at ₹254.25 after shedding ₹1.00 or 0.39%. The stock has seen active movement today, with over 1.39 million shares traded in the market.